Author(s): Nigama Chandra Sattenapalli, Ranjit Prasad Swain, Siva Naga Koteswara Rao Gudhanti

Email(s): ranjit.prasad797@gmail.com

DOI: 10.52711/0974-360X.2022.00823   

Address: Nigama Chandra Sattenapalli1, Ranjit Prasad Swain2*, Siva Naga Koteswara Rao Gudhanti1
1Department of Pharmaceutics, K L College of Pharmacy, Koneru Lakshmaiah Education Foundation, Vaddeswaram, A.P., India.
2Department of Pharmaceutics, School of Pharmaceutical Sciences, Siksha O Anusandhan (Deemed to be University), Bhubaneswar, Odisha, India.
3Department of Pharmacy, School of Medical and Allied Sciences, Galgotias University, Greater Noida, UP, India.
*Corresponding Author

Published In:   Volume - 15,      Issue - 11,     Year - 2022


ABSTRACT:
The main purpose of the present review is to compile the recent information with special focus on different aspects of muscular dystrophy. Muscular dystrophies are the group of genetic disorders that causes progressive muscle weakness and degeneration of skeletal muscles, restricts their movement and functions, and is irreversible. There is no clear picture and statistics on muscular dystrophy effected individuals especially in India. This article specifies and acknowledges the muscular dystrophy facts and particulars all over the world especially focusing the story in India. The study is based on statistics taken from several reports gathered by different organizations in India, as well as, from other data sources published. In this regard, this present review highlighted the areas of epidemiology, present scenario of prevalence, types of muscular dystrophy specially focused on genetic involment, identification of clinical symptoms, clinical diagnosis specially focused in India, care, management and treatment of this disorder.


Cite this article:
Nigama Chandra Sattenapalli, Ranjit Prasad Swain, Siva Naga Koteswara Rao Gudhanti. Bridging between disorder, prevalence, clinical manifestation and therapeutic management of muscular dystrophy. Research Journal of Pharmacy and Technology. 2022; 15(11):4901-7. doi: 10.52711/0974-360X.2022.00823

Cite(Electronic):
Nigama Chandra Sattenapalli, Ranjit Prasad Swain, Siva Naga Koteswara Rao Gudhanti. Bridging between disorder, prevalence, clinical manifestation and therapeutic management of muscular dystrophy. Research Journal of Pharmacy and Technology. 2022; 15(11):4901-7. doi: 10.52711/0974-360X.2022.00823   Available on: https://rjptonline.org/AbstractView.aspx?PID=2022-15-11-8


REFERENCES:
1.    Muscular dystrophy information page. Available on http://www.ninds.nih.gov/disorders/md/md.htm accessed on 24.04.2020.
2.    Nigro G. One-hundred-seventy-five years of Neapolitan contributions to the fight against the muscular diseases. Acta Myologica. 2010; 29: 369-391.
3.    Conte G, Gioja L. Scrofola del sistema muscolare. Annali Clinici dell'Ospedale degli Incurabili di Napoli 1836; 2:66-79.
4.    Semmola G. Sopra due malattie. Notiziedell’atrainfermita, AcadPontaniana.1834:164-165.
5.    Meryon E. On granular and fatty degeneration of the voluntary muscles. Medico-Chirurgical Transactions.1852; 35:73-74.
6.    Huml RA. Muscular dystrophy: historical background and types, In Muscular dystrophy, Edited by Huml R. Springer, Switzerland. 2015; 1st ed: pp. 5-7.
7.    Twee T Do. Muscular dystrophy. Available on http://emedicine.medscape.com/article/1259041-overview. Accessed on 28.03.2020.
8.    Duchenne GBA. Recherches sur la paralysiemusculaire pseudo-hypertrophiqueouparalysie myo-sclerosique. Archives of general Medicine.1868; 11:5-25.
9.    Griggs RC, Amato AA. Handbook of clinical neurology. Elsevier, Netherlands. 2011.
10.    Nalini A, Polavarapu K, Preethish-Kumar V. Muscular dystrophies: An Indian scenario. Neurol India. 2017; 65:969-970. doi.org/10.4103/neuroindia.ni_733_17
11.    Centers for disease control and prevention (CDC), Prevalence of duchenne/becker muscular dystrophy among males aged 5-24 years – four states, 2007, Morbidity and mortality weekly report. 2009; 58:1119-1122. PMID: 19834452.
12.    Barber BJ, et al. oral corticosteroids and onset of cardiomyopathy in duchenne muscular dystrophy external icon. Journal of Pediatrics. 2013; 163:1080-1084. doi.org/10.1016/j.jpeds.2013.05.060
13.    Wicklund MP. The muscular dystrophies. Continuum: Monneap Minn. 2013;19:1535-1570. doi.org/10.1212/01.con.0000440659.41675.8b
14.    Romitti PA, et al. Prevalence of Duchenne and Becker muscular dystrophies in the United States external icon. Pediatrics. 2015; 135 513-521. doi.org/10.1542/peds.2014-2044
15.    Nigro V, Savarese M. Genetic basis of limb-girdle muscular dystrophies: the 2014 update. Acta Myologica. 2014; 33:1-12. PMID:24843229
16.    Limb-girdle muscular dystrophy. Available on https://www.mda.org/sites/default/files/2019/06/MDA_LGMD_Fact_Sheet_June_2019.pdf. accessed on 17.06.2019.
17.    Kim S, et al. Corticosteroid treatments in males with duchenne muscular dystrophy: Treatment duration and time to loss of ambulation. Journal of Child Neurology. 2015; 30:1275-1280. doi.org/10.1177%2F0883073814558120
18.    Scenario of prevalence, Amaravathi Muscular dystrophy association. Andhra Pradesh. Available on http://amda-india.org/. accessed on 28.12.2019.
19.    Emery AE. Population frequencies of inherited neuromuscular diseases: A world survey. Neuromuscular Disorder. 1991; 1:19-29. doi.org/10.1016/0960-8966(91)90039-u
20.    Miller LA. et al. The muscular dystrophy surveillance tracking and research network.MD STARnet: surveillance methodology. Birth Defects Research Part A Clinical molecular Teratology. 2006;76:793-797. doi.org/10.1002/bdra.20279
21.    Moser H. Duchenne muscular dystrophy: pathogenic aspects and genetic prevention. Human Genetics. 1984; 66:17-40. doi.org/10.1007/bf00275183
22.    Bushby KM, Thmabyayah M, Gardner MD. Prevalence and incidence of becker muscular dystrophy. Lancet. 1991; 337:1022-1024. doi.org/10.1016/0140-6736(91)92671-n
23.    Ciafaloni E, et al. Delayed diagnosis in duchenne muscular dystrophy: data from the muscular dystrophy surveillance, tracking, and research network (MD STARnet). Journal of Pediatrics. 2009; 155:380-385. doi.org/10.1016/j.jpeds.2009.02.007
24.    Facioscapulohumeral Muscular Dystrophy (FSH, FSHD). Available on https://www.mda.org/disease/facioscapulohumeral-muscular-dystrophy accessed on 24.3.2020.
25.    Brais B. Oculopharyngeal muscular dystrophy: a polyalanine myopathy. Current Neurology and Neuroscience Reports. 2009; 9:76-82. doi.org/10.1007/s11910-009-0012-y
26.    Limb-Girdle Muscular Dystrophy (LGMD). Available on https://www.mda.org/disease/limb-girdle-muscular-dystrophy, accessed on 21.02.2020.
27.    Eagle M, et al. Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation. Neuromuscular Disorder. 2002; 12:926-929. doi.org/10.1016/s0960-8966(02)00140-2
28.    Wong BL, Christopher C. Corticosteroids in Duchenne muscular dystrophy: a reappraisal. Journal of Child Neurology. 2002; 17:183-190. doi.org/10.1177/088307380201700306
29.    Koenig M, et al. Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell. 1987; 50:509-517. doi.org/10.1016/0092-8674(87)90504-6
30.    Den Dunnen JT, et al. Topography of the Duchenne muscular dystrophy (DMD) gene:FIGE and cDNA analysis of 194 cases reveals 115 deletions and 13 duplications. American Journal of Human Genetics. 1989; 45:835-847. PMID:2573225.
31.    Akbari MT, et al. Molecular diagnosis of Duchenne/Becker Muscular Dystrophy: Analysis of exon deletion and carrier detection. Cell journal (Yakhte) 2010; 12: 421-428. Available on https://www.sid.ir/en/journal/ViewPaper.aspx?id=183150
32.    Helderman-van den E, et al. Becker muscular dystrophy deletions around exon 51; a promising outlook for exon skipping therapy in Duchenne patients. Neuromuscular disorders. 2010;20: 251-254. doi.org/10.1016/j.nmd.2010.01.013
33.    Aartsma-Rus A, et al. Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. Human Mutation. 2009; 30:293-299. doi.org/10.1002/humu.20918
34.    Van DJC, et al. Local dystrophin restoration with antisense oligonucleotide PRO051. New England Journal of Medicine. 2007; 357:2677-2686. doi.org/10.1056/nejmoa073108
35.    Kooi van der AJ, et al. The clinical spectrum of limb girdle muscular dystrophy. A survey in the Netherlands. Brain. 1996; 119:1471-1480. doi.org/10.1093/brain/119.5.1471
36.    Reilich P, et al. A novel mutation in the myotilin gene (MYOT) causes a severe form of limb girdle muscular dystrophy 1A (LGMD1A). Journal of Neurology. 2011;  258: 1437-1444. doi.org/10.1007/s00415-011-5953-9
37.    Vainzof  M, et al. Sarcoglycanopathies are responsible for 68% of severe autosomal recessive limb-girdle muscular dystrophy in the Brazilian population. Journal of Neurolpgical Sciences. 1999; 164:44-49. doi.org/10.1016/S0022-510X(99)00040-4
38.    Amberger J, Bocchini C, Hamosh A. A new face and new challanges for online Mendelian Inheritance in Man (OMIM®). Human Mutation. 2011; 32:564-567. doi.org/10.1002/humu.21466
39.    Duggan DJ, et al. Mutations in the sarcoglycan genes in patients with myopathy. New England Journal of Medicine. 1997; 336:618-24. doi.org/10.1056/nejm199702273360904
40.    Zatz M. The 10 autosomal recessive limb-girdle muscular dystrophies. Neuromuscular Disorder. 2003; 13:532-544. doi.org/10.1016/s0960-8966(03)00100-7
41.    Weiler T, et al. A gene for autosomal recessive limb-girdle muscular dystrophy in Manitoba Hutterites maps to chromosome region 9q31-q33: evidence for another limb-girdle muscular dystrophy locus. American Journal of Human Genetics. 1998; 63:140-147. doi.org/10.1086%2F301925
42.    Saccone V, et al. Mutations that impair interaction properties of TRIM32 associated with limb-girdle muscular dystrophy type 2H. Human Mutation. 2008; 29:240-247. doi.org/10.1002/humu.20633
43.    Brockington M. Mutations in the fukutin-related protein gene (FKRP) identify limb girdle muscular dystrophy 2I as a milder allelic variant of congenital muscular dystrophy MDC1C. Human Molecular Genetics. 2001; 10:2851-2859. doi.org/10.1093/hmg/10.25.2851
44.    Poppe M, et al. Cardiac and respiratory failure in limb-girdle muscular dystrophy 2I. Annals of Neurology. 2004; 56:738-741. doi.org/10.1002/ana.20283
45.    Godfrey C, et al. Refining genotype phenotype correlations in muscular dystrophies with defective glycosylation of dystroglycan. Brain. 2007; 130:2725-2735. doi.org/10.1093/brain/awm212
46.    Hicks D, et al. A founder mutation in Anoctamin 5 is a major cause of limb-girdle muscular dystrophy. Brain, 2011; 134:171-182. doi.org/10.1093/brain/awq294
47.    Godfrey C, et al. Fukutin gene mutations in steroid-responsive limb girdle muscular dystrophy. Annals of Neurology. 2006; 60: 603-610. doi.org/10.1002/ana.21006
48.    Biancheri R, et al. POMT2 gene mutation in limb-girdle muscular dystrophy with inflammatory changes. Biochemical and Biophysical Research Communications. 2007; 363:1033-1037. doi.org/10.1016/j.bbrc.2007.09.066
49.    Gundesli H, et al. Mutation in exon 1f of PLEC, leading to disruption of plectin isoform 1f, causes autosomal-recessive limb girdle muscular dystrophy.  American Journal of Human Genetics. 2010; 87:834-841. doi.org/10.1016/j.ajhg.2010.10.017






Recomonded Articles:

Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal.... Read more >>>

RNI: CHHENG00387/33/1/2008-TC                     
DOI: 10.5958/0974-360X 

0.38
2018CiteScore
 
56th percentile
Powered by  Scopus


SCImago Journal & Country Rank


Recent Articles




Tags


Not Available